1. Home
  2. TCMD vs ACRS Comparison

TCMD vs ACRS Comparison

Compare TCMD & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$31.49

Market Cap

533.5M

Sector

Health Care

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.62

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
ACRS
Founded
1995
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.5M
608.9M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
TCMD
ACRS
Price
$31.49
$5.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$36.00
$10.20
AVG Volume (30 Days)
223.1K
2.0M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
17.14
69.01
EPS
N/A
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
$11.60
N/A
Revenue Next Year
$9.14
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.42
$1.46
52 Week High
$37.77
$5.69

Technical Indicators

Market Signals
Indicator
TCMD
ACRS
Relative Strength Index (RSI) 75.14 72.77
Support Level $25.34 $4.13
Resistance Level $37.77 N/A
Average True Range (ATR) 1.27 0.30
MACD 0.43 0.10
Stochastic Oscillator 87.85 91.44

Price Performance

Historical Comparison
TCMD
ACRS

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: